Medplus Health Services: MedPlus Credit Rating: CareEdge Reaffirms Optival’s Ratings on Rs 250
MedPlus disclosed CareEdge’s reaffirmation of ratings on subsidiary Optival’s Rs 250 crore bank facilities, with a stable outlook on long-term debt.

MedPlus Health Services Ltd, in a BSE filing dated October 3, 2026, disclosed that CareEdge Ratings Limited had reaffirmed the credit ratings on bank facilities of its material subsidiary, Optival Health Solutions Private Limited. The MedPlus credit rating disclosure covers long-term and short-term bank facilities totalling Rs 250 crore.
CareEdge reaffirmed the rating on Optival’s Rs 236 crore long-term bank facilities at CARE A; Stable. It also reaffirmed the rating on Rs 14 crore of short-term bank facilities at CARE A1, according to the filing.
Both rating actions were recorded as reaffirmations. The stable outlook accompanies the long-term facility rating; the short-term facilities were separately listed with the CARE A1 rating.
Optival’s bank facility ratings
| Facility | Amount | Rating | Action |
|---|---|---|---|
| Long-term bank facilities | Rs 236 crore | CARE A; Stable | Reaffirmed |
| Short-term bank facilities | Rs 14 crore | CARE A1 | Reaffirmed |
The rated entity identified in the disclosure is Optival Health Solutions Private Limited. MedPlus submitted the information as the listed parent company and described Optival as its material subsidiary. The facility amounts and ratings in the disclosure therefore relate to Optival.
The Rs 250 crore combined amount comprises the two bank facility categories listed in the filing. The disclosure reports their credit ratings and corresponding rating actions; it does not describe the amounts as newly sanctioned borrowing or funds raised.
Disclosure to BSE and NSE
MedPlus said CareEdge Ratings Limited, formerly CARE Ratings Limited, communicated the ratings by email. The company submitted the intimation under Regulation 30, read with Para A of Part A of Schedule III of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The communication was addressed to BSE Limited and the National Stock Exchange of India Limited. MedPlus is identified in the filing by BSE scrip code 543427 and NSE symbol MEDPLUS.
Shrenik Soni, Company Secretary and Compliance Officer, signed the filing. MedPlus said the information would also be available on its website and the websites of both exchanges.
